792P Analysis of postoperative adjuvant chemotherapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study

ObjectiveGastric-type mucinous carcinoma (GAS) is a novel variant of mucinous carcinoma of the uterine cervix, characterized by aggressive clinical behavior and absence of high-risk human papillomavirus. We conducted this study to evaluate the chemosensitivity of GAS compared with that of usual-type endocervical adenocarcinoma (UEA) in patients who had been enrolled in our previous study.MethodsOf 52 patients from our previous phase 2 study (SGSG005) of neoadjuvant chemotherapy with docetaxel and carboplatin for stage IB2 to IIB nonsquamous cervical cancer, 47 (stage IB2, 12; stage IIA2, 7; stage IIB, 28) were enrolled in this study with written informed consent. The biopsy specimens before neoadjuvant chemotherapy and surgical specimens after chemotherapy were centrally reviewed based on the updated World Health Organization classification (2014).ResultsOf 47 patients with nonsquamous cell carcinoma, 20 (42.6%) were diagnosed with UEA, 13 (27.7%) with GAS, 12 (25.5%) with adenosquamous carcinoma, and 1 patient each (2%) with small cell carcinoma and serous carcinoma. Consequently, 33 patients, consisting of 20 patients with UEA and 13 patients with GAS, were eligible for the current study. The response rate of GAS was significantly lower than that of UEA (46.2% vs 85.0%, P = 0.048). Of 16 cases of stage II UEA, 11 (68.8%) were downstaged on microscopic examination of postsurgical specimens, but none of the 8 patients with stage II GAS showed any response (P < 0.01). Two inoperative tumors were GAS. With a median follow-up duration of 56 months, the 5-year progression-free and overall survival rates of GAS were significantly worse than those of UEA (38.5% vs 75.0% [P = 0.011] and 36.9% vs 90.0% [P < 0.001], respectively).ConclusionsThese findings suggest that GAS should be distinguished from UEA by its chemoresistance, necessitating an alternative treatment strategy established for this distinct subtype of endocervical adenocarcinoma.

Download Full-text

Analysis of gastric-type mucinous carcinoma of the uterine cervix — An aggressive tumor with a poor prognosis: A multi-institutional study

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.01.022 ◽

2019 ◽

Vol 153 (1) ◽

pp. 13-19 ◽

Cited By ~ 16

Author(s):

Shin Nishio ◽

Yoshiki Mikami ◽

Hideki Tokunaga ◽

Nobuo Yaegashi ◽

Toyomi Satoh ◽

...

Keyword(s):

Uterine Cervix ◽

Poor Prognosis ◽

Mucinous Carcinoma ◽

Gastric Type ◽

Aggressive Tumor

Download Full-text

Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix

Cancer Genomics & Proteomics ◽

10.21873/cgp.20219 ◽

2020 ◽

Vol 17 (5) ◽

pp. 627-641

Author(s):

HERA JUNG ◽

GO EUN BAE ◽

HYE MIN KIM ◽

HYUN-SOO KIM

Keyword(s):

Uterine Cervix ◽

Mucinous Carcinoma ◽

Usual Type ◽

Endocervical Adenocarcinoma ◽

Gastric Type

Download Full-text

A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphatic Invasion

Case Medical Research ◽

10.31525/ct1-nct04255771 ◽

2020 ◽

Author(s):

Keyword(s):

Adjuvant Chemotherapy ◽

Urothelial Carcinoma ◽

Lymphatic Invasion ◽

Postoperative Adjuvant Chemotherapy

Download Full-text

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study

Medicina ◽

10.3390/medicina57060548 ◽

2021 ◽

Vol 57 (6) ◽

pp. 548

Author(s):

Masahiro Kagabu ◽

Takayuki Nagasawa ◽

Shunsuke Tatsuki ◽

Yasuko Fukagawa ◽

Hidetoshi Tomabechi ◽

...

Keyword(s):

Cervical Cancer ◽

Lymph Node ◽

Adjuvant Chemotherapy ◽

Lymph Node Metastasis ◽

Radical Hysterectomy ◽

Concurrent Chemoradiotherapy ◽

Postoperative Adjuvant Chemotherapy ◽

Node Metastasis ◽

Significant Difference ◽

Advanced Stages

Background and Objectives: In October 2018, the International Federation of Gynecology and Obstetrics (FIGO) revised its classification of advanced stages of cervical cancer. The main points of the classification are as follows: stage IIIC is newly established; pelvic lymph node metastasis is stage IIIC1; and para-aortic lymph node metastasis is stage IIIC2. Currently, in Japan, radical hysterectomy is performed in advanced stages IA2 to IIB of FIGO2014, and concurrent chemoradiotherapy (CCRT) is recommended for patients with positive lymph nodes. However, the efficacy of CCRT is not always satisfactory. The aim of this study was to compare postoperative adjuvant chemotherapy (CT) and postoperative CCRT in stage IIIC1 patients. Materials and Methods: Of the 40 patients who had undergone a radical hysterectomy at Iwate Medical University between January 2011 and December 2016 and were pathologically diagnosed as having positive pelvic lymph nodes, 21 patients in the adjuvant CT group and 19 patients in the postoperative CCRT group were compared. Results: The 5 year survival rates were 77.9% in the CT group and 74.7% in the CCRT group, with no significant difference. There was no significant difference in overall survival or progression-free survival between the two groups. There was no significant difference between CT and CCRT in postoperative adjuvant therapy in the new classification IIIC1 stage. Conclusions: The results of the prospective Japanese Gynecologic Oncology Group (JGOG) 1082 study are pending, but the present results suggest that CT may be a treatment option in rural areas where radiotherapy facilities are limited.

Download Full-text